Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

Fertil Steril. 2001 Nov;76(5):1057-9. doi: 10.1016/s0015-0282(01)02843-6.


Objective: To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).

Design: Case report.

Setting: Academic clinical practice and General Clinical Research Center.

Patient(s): A 25-year-old woman with PCOS.

Intervention(s): Rosiglitazone maleate, 4 mg daily for 5 months until conception.

Main outcome measure(s): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.

Result(s): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.

Conclusion(s): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / physiology*
  • Ovulation*
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology*
  • Pregnancy*
  • Rosiglitazone
  • Thiazoles / therapeutic use*
  • Thiazolidinediones*


  • Hypoglycemic Agents
  • Insulin
  • Thiazoles
  • Thiazolidinediones
  • Rosiglitazone